110 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2006 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 7 PROPERTY, PLANT AND EQUIPMENT Land and Plant and Assets in course Total property, plant buildings equipment of construction and equipment $m $m $m $m Cost At 1 January 2004 4,128 7,981 948 13,057 Capital expenditure 17 205 851 1,073 Transfer of assets into use 430 641 1,071 Disposals and other movements 55 335 6 396 Exchange adjustments 281 590 45 916 At 31 December 2004 4,801 9,082 767 14,650 Capital expenditure 13 150 669 832 Transfer of assets into use 257 594 851 Disposals and other movements 99 820 14 933 Exchange adjustments 482 971 91 1,544 At 31 December 2005 4,490 8,035 480 13,005 Capital expenditure 23 196 577 796 Additions through business combinations 26 26 Transfer of assets into use 154 494 648 Disposals and other movements 35 300 3 338 Exchange adjustments 450 912 57 1,419 At 31 December 2006 5,082 9,363 463 14,908 Depreciation At 1 January 2004 1,139 4,371 5,510 Charge for year 172 749 921 Impairment 31 31 Disposals and other movements 37 302 339 Exchange adjustments 86 344 430 At 31 December 2004 1,360 5,193 6,553 Charge for year 166 799 965 Impairment 90 90 Disposals and other movements 53 794 847 Exchange adjustments 153 588 741 At 31 December 2005 1,320 4,700 6,020 Charge for year 203 747 950 Impairment 6 47 53 Disposals and other movements 21 277 298 Exchange adjustments 148 582 730 At 31 December 2006 1,656 5,799 7,455 Net book value At 31 December 2004 3,441 3,889 767 8,097 At 31 December 2005 3,170 3,335 480 6,985 At 31 December 2006 3,426 3,564 463 7,453 Impairment charges in 2006 are attributable to the write-down of assets in relation to the termination of NXY-059 and the write-down of assets in association with Toprol-XL, resulting from the introduction of generic competition in the US.
The charges were recognised in cost of sales in the income statement.
Impairment charges in 2005 relate to the write-down of assets associated with capacity reviews at manufacturing sites, primarily in the UK and France.
These were recognised in cost of sales in the income statement.
The impairment charge in 2004 was made to write-off assets associated with Iressa.
This was recognised in cost of sales in the income statement.
